{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Gao C"],"funding":["This study was funded by CSPC Ouyi pharmaceutical Co., Ltd."],"pubmed_abstract":["In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel. The primary endpoint was progression free survival (PFS). Secondary endpoints included other efficacy outcomes (overall survival, objective response rate, disease control rate, and duration of response), as well as safety, pharmacokinetic parameters, and evaluation of the relationship between UGT1A1*6 and UGT1A1*28 polymorphisms and safety. A total of 117 patients were enrolled and randomly assigned to NALIRIFOX (n = 78) or gemcitabine plus nab-paclitaxel (n = 39). At a median follow-up of 18.7 months (interquartile range [IQR], 7.5-22.1) for NALIRIFOX and 12.1 "],"journal":["Nature communications"],"pagination":["1715"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12913728"],"repository":["biostudies-literature"],"pubmed_title":["NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial."],"pmcid":["PMC12913728"],"pubmed_authors":["Lin R","Hao J","Zhang J","Wang B","Zhang H","Gao J","Liu R","Zhao T","Cheng W","Yu J","Wang J","Gao C","Shi X","Wu H","Ma W","Shi Y","Sun M","Liu Y","Wu S","Zhao F","Qu X","Chen X","Wang X","Niu M","Wang Y","Yuan X","Zhao J","Xie Y","Zha Y","Li Z","Yang Y","Du C","Zhang Y","Gao S","Zang A"],"additional_accession":[]},"is_claimable":false,"name":"NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.","description":"In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel. The primary endpoint was progression free survival (PFS). Secondary endpoints included other efficacy outcomes (overall survival, objective response rate, disease control rate, and duration of response), as well as safety, pharmacokinetic parameters, and evaluation of the relationship between UGT1A1*6 and UGT1A1*28 polymorphisms and safety. A total of 117 patients were enrolled and randomly assigned to NALIRIFOX (n = 78) or gemcitabine plus nab-paclitaxel (n = 39). At a median follow-up of 18.7 months (interquartile range [IQR], 7.5-22.1) for NALIRIFOX and 12.1 ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-16T06:55:02.13Z","creation":"2026-07-09T10:43:25.303Z"},"accession":"S-EPMC12913728","cross_references":{"pubmed":["41545349"],"doi":["10.1038/s41467-026-68409-0"]}}